IQVIA Holdings Inc is known for its strong values and corporate philosophy. The company emphasizes innovation, integrity, and collaboration. With a commitment to advancing healthcare, IQVIA strives to improve patient outcomes and support the life sciences industry. By combining cutting-edge technology, data analytics, and deep industry expertise, IQVIA delivers actionable insights and solutions to its clients. The company's dedication to ethical practices, global impact, and teamwork sets it apart in the market. IQVIA Holdings Inc continuously works towards transforming healthcare through its core values and corporate philosophy.

IQVIA Holdings Inc is primarily present in various countries and regions across the globe. As a leading provider of advanced analytics, technology solutions, and clinical research services, IQVIA operates in more than 100 countries worldwide. With a strong presence in North America, Europe, Asia-Pacific, and the Middle East, IQVIA caters to the needs of pharmaceutical, biotechnology, and healthcare companies across these regions. The company's extensive global reach positions it well to support and collaborate with clients on a global scale.

IQVIA Holdings Inc has achieved several significant milestones in its history. One notable achievement is the merger between IMS Health and Quintiles Transnational in 2016, which led to the formation of IQVIA. This merger created a leading global provider of advanced analytics, technology solutions, and contract research services to the healthcare industry. Another milestone is the company's consistent focus on innovation and cutting-edge research. IQVIA has pioneered groundbreaking solutions in areas such as real-world evidence, patient centricity, and digital health. Additionally, IQVIA has expanded its global footprint and established a strong presence in key markets worldwide. These achievements have solidified IQVIA Holdings Inc as a frontrunner in the healthcare and life sciences industry.

IQVIA Holdings Inc, formerly known as Quintiles IMS Holdings Inc, is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. The company was formed in 2016 through the merger of Quintiles Transnational Holdings Inc and IMS Health Holdings Inc. With a history dating back to 1982, IQVIA has been at the forefront of transforming the way pharmaceutical, biotechnology, and healthcare companies operate. Today, IQVIA leverages its extensive data, domain expertise, and innovative technologies to improve clinical trial outcomes, enhance real-world evidence solutions, and drive healthcare intelligence for its clients.

The main competitors of IQVIA Holdings Inc in the market include companies such as LabCorp, PRA Health Sciences, ICON PLC, and Syneos Health.

IQVIA Holdings Inc is primarily active in the healthcare and pharmaceutical industries. With its comprehensive range of services and solutions, IQVIA plays a crucial role in supporting the advancement of healthcare worldwide. As a leading provider of integrated information and technology-enabled solutions, IQVIA assists pharmaceutical companies, healthcare providers, and researchers in optimizing their operations and making informed decisions. With its vast expertise and global presence, IQVIA continues to drive innovation, improve patient outcomes, and contribute to the overall growth and development of the healthcare industry.

The business model of IQVIA Holdings Inc is focused on providing advanced analytics, technology solutions, and contract research services to the life sciences industry. IQVIA offers a wide range of services, including clinical trial support, real-world evidence solutions, commercial effectiveness, and healthcare data management. Through leveraging its vast network of healthcare professionals and extensive data resources, IQVIA helps pharmaceutical, biotech, and medical device companies navigate the complex healthcare landscape, drive innovation, and improve patient outcomes.

IQVIA Holdings의 P/E 비율은 21.96입니다.

IQVIA Holdings의 P/S 비율은 2.9입니다.

IQVIA Holdings에 대한 AlleAktien 품질 점수는 7/10입니다.

예상되는 IQVIA Holdings 매출은 15.63 조. USD입니다.

예상되는 IQVIA Holdings 이익은 2.06 조. USD입니다.

IQVIA Holdings Inc. is a global leader in the healthcare industry. It combines biomedical insights in innovative ways to improve global health. IQVIA offers various divisions, including research and analysis solutions, technology platforms, clinical development, and commercial support. Its mission is to enhance patient care while reducing healthcare costs. The company provides a wide range of products and services tailored to customer needs, with the overarching goal of improving patient outcomes worldwide.

IQVIA Holdings은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

IQVIA Holdings의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

IQVIA Holdings의 ISIN은 US46266C1053입니다.

IQVIA Holdings의 WKN은 A2JSPM입니다.

IQVIA Holdings의 티커는 IQV입니다.

지난 12개월 동안 IQVIA Holdings은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 IQVIA Holdings은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

IQVIA Holdings의 현재 배당 수익률은 입니다.

IQVIA Holdings은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

IQVIA Holdings은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

IQVIA Holdings은 '건강' 섹터에 속합니다.

IQVIA Holdings의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 IQVIA Holdings는 0 USD를 배당금으로 지급했습니다.

IQVIA Holdings의 배당금은 USD에 지급됩니다.